Syndax Pharmaceuticals, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for SNDX, updated each market day.
SNDX AI Sentiment
AI sees no strong directional signal for Syndax Pharmaceuticals, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Sector
Exchange
Market Cap
$2,183,846,756
Cap Tier
Employees
298
Headquarters
NEW YORK, NY
Listed Since
March 3, 2016
Website
SNDX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SNDX Volatility
Syndax Pharmaceuticals, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
